Table 2 Transition between biologic DMARDs during Corrona follow-up, 2002–2019
First bDMARD | DMARD use after baseline, as noted every 6 months on Corrona case report forms | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
0 months | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months | 42 months | 48 months | 54 months | 60 months | |
(n = 7300) | (n = 7250) | (n = 6435) | (n = 5769) | (n =5153) | (n = 4658) | (n = 4175) | (n = 3723) | (n = 3359) | (n = 3054) | (n = 2764) | |
TCZ monotherapy | 66 (0.90) | 78 (1.08) | 45 (0.70) | 37 (0.64) | 21 (0.41) | 25 (0.54) | 23 (0.55) | 18 (0.48) | 12 (0.36) | 17 (0.56) | 8 (0.29) |
TCZ combination | 117 (1.60) | 128 (1.77) | 117 (1.82) | 122 (2.11) | 123 (2.39) | 109 (2.34) | 97 (2.32) | 67 (1.80) | 59 (1.76) | 47 (1.54) | 45 (1.63) |
TNFi, any | 5889 (80.67) | 4725 (65.17) | 4000 (62.16) | 3423 (59.33) | 2980 (57.83) | 2639 (56.66) | 2284 (54.71) | 1989 (53.42) | 1764 (52.52) | 1576 (51.6) | 1402 (50.72) |
nonTNF nonTCZ bDMARD | 1228 (16.82) | 1137 (15.68) | 1027 (15.96) | 938 (16.26) | 852 (16.53) | 802 (17.22) | 749 (17.94) | 707 (18.99) | 671 (19.98) | 609 (19.94) | 575 (20.8) |
csDMARD combination | – | 946 (13.05) | 996 (15.48) | 998 (17.3) | 946 (18.36) | 880 (18.89) | 812 (19.45) | 761 (20.44) | 690 (20.54) | 657 (21.51) | 597 (21.6) |
No DMARD | – | 236 (3.26) | 250 (3.89) | 251 (4.35) | 231 (4.48) | 203 (4.36) | 210 (5.03) | 181 (4.86) | 163 (4.85) | 148 (4.85) | 137 (4.96) |